Finasteride

• Description :

  Finasteride (MK-906) is an orally active and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia[1][2][3].

• Product Name Alternative :

  MK-906

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  5 alpha Reductase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/finasteride.html

• Purity :

  99.97

• Solubility :

  DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL (ultrasonic)

• Smiles :

  O=C([C@H]1CC[C@]2([H])[C@]1(C)CC[C@]3([H])[C@@]4(C)C=CC(N[C@]4([H])CC[C@]32[H])=O)NC(C)(C)C

• Molecular Formula :

  C23H36N2O2

• Molecular Weight :

  372.54

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Flores E, et, al. Steroid 5alpha-reductase inhibitors. Mini Rev Med Chem. 2003 May;3 (3) :225-37.|[2]Yun DK, et, al. Finasteride Increases the Expression of Hemoxygenase-1 (HO-1) and NF-E2-Related Factor-2 (Nrf2) Proteins in PC-3 Cells: Implication of Finasteride-Mediated High-Grade Prostate Tumor Occurrence. Biomol Ther (Seoul) . 2013 Jan;21 (1) :49-53.|[3]Sirinarumitr K, et, al. Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy. J Am Vet Med Assoc. 2001 Apr 15;218 (8) :1275-80.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [98319-26-7]